Czarnecka-Operacz Magdalena, Sadowska-Przytocka Anna
Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland. Head of the Department: Prof. Zygmunt Adamski MD, PhD ; Laboratory of Allergic Skin Diseases, Poznan University of Medical Sciences, Poznan, Poland. Head of the Laboratory: Prof. Magdalena Czarnecka-Operacz.
Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland. Head of the Department: Prof. Zygmunt Adamski MD, PhD.
Postepy Dermatol Alergol. 2014 Dec;31(6):392-400. doi: 10.5114/pdia.2014.47121. Epub 2014 Dec 3.
Psoriasis is a chronic multifactorial disease affecting 2-4% of the general population. Due to its nature, psoriasis has a negative impact on the quality of life of patients. Therefore, the choice of an appropriate and individually tailored treatment controlling the symptoms of the disorder is necessary and continues to be a challenge for dermatologists. Therapeutic modalities in psoriasis should on the one hand be effective and on the other hand present a good safety profile. Methotrexate (MTX) is one of treatment options for psoriasis and can be administered both as monotherapy or in combination schemes. The paper presents the current state of knowledge about the possible treatment of psoriatic patients with MTX according to contemporary guidelines.
银屑病是一种慢性多因素疾病,影响着2%至4%的普通人群。因其特性,银屑病会对患者的生活质量产生负面影响。因此,选择一种合适的、个性化定制的治疗方法来控制该疾病的症状是必要的,并且这对皮肤科医生来说仍然是一个挑战。银屑病的治疗方式一方面应有效,另一方面应具有良好的安全性。甲氨蝶呤(MTX)是银屑病的治疗选择之一,可作为单一疗法或联合方案使用。本文根据当代指南介绍了关于用MTX治疗银屑病患者的现有知识状况。